<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00082459</url>
  </required_header>
  <id_info>
    <org_study_id>C-100-23</org_study_id>
    <nct_id>NCT00082459</nct_id>
  </id_info>
  <brief_title>Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma</brief_title>
  <official_title>A Randomized Phase II Study Investigating the Route of Administration of Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agenus Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Agenus Inc.</source>
  <brief_summary>
    <textblock>
      The goal of this trial is to determine the safety of HSPPC-96 and which route of&#xD;
      administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic&#xD;
      agent made from an individual patient's tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this trial is to determine the safety of HSPPC-96 and which route of&#xD;
      administration achieves a better response with the vaccine. HSPPC-96 is an immunotherapeutic&#xD;
      agent made from an individual patient's tumor. The study is being conducted in Houston, Texas&#xD;
      with patients enrolled into one of two treatment arms. The two treatment arms are either&#xD;
      subcutaneous injection or intradermal injection, both with HSPPC-96. To be treated with&#xD;
      HSPPC-96 patients must undergo surgery to remove the kidney tumor and a portion of this&#xD;
      tissue will be sent to Antigenics' manufacturing facility for processing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of enrollment&#xD;
  </why_stopped>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">December 2005</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>40</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous human tumor-derived HSPPC-96</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suspected metastatic renal cell carcinoma (AJCC Stage IV) with intact primary tumor&#xD;
&#xD;
          -  No previous therapy for metastatic renal cell carcinoma&#xD;
&#xD;
          -  Measurable disease (RECIST criteria)&#xD;
&#xD;
          -  Primary tumor greater than or equal to 7cm on CT or MRI&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  At least 18 years old&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Adequate cardiac function (NYHA I-II)&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Provide written informed consent&#xD;
&#xD;
          -  Absence of multiple liver metastases, brain or threatening bone metastases (axial&#xD;
             skeleton and/or pathological features)&#xD;
&#xD;
          -  Planned complete nephrectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of primary or secondary immunodeficiency, or patients using systemic&#xD;
             corticosteroids or cyclosporin A&#xD;
&#xD;
          -  Other cancer (including renal cell carcinoma) within the last five years (with the&#xD;
             exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or&#xD;
             basal or squamous cell carcinoma of the skin)&#xD;
&#xD;
          -  Embolization of the renal artery prior to nephrectomy&#xD;
&#xD;
          -  Active, uncontrolled infection or other serious medical illnesses, preventing study&#xD;
             completion, in the opinion of the Principal Investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>May 10, 2004</study_first_submitted>
  <study_first_submitted_qc>May 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2004</study_first_posted>
  <last_update_submitted>September 6, 2012</last_update_submitted>
  <last_update_submitted_qc>September 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Kidney Cancer</keyword>
  <keyword>Renal</keyword>
  <keyword>Tumor</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

